According to CoinMeta, Johnson & Johnson ( JNJ.US ) Q3 exceeded earnings expectations and raised its full-year performance guidance! The innovative drug business has seen growth, while the medical device business still needs improvement. On Tuesday before the U.S. stock market opened, Johnson & Johnson ( JNJ.US ) announced third-quarter 2026 results that were better than expected, and raised its full-year 2026 revenue and earnings guidance. The financial report showed that Johnson & Johnson's sales in the third quarter increased by 5.9% year-on-year to $25.4 billion, in line with market expectations. In terms of earnings, net profit under the GAAP metric plummeted by 95.9% year-on-year to $210 million, with diluted earnings per share at just $0.09 (compared to $2.12 in the same period last year), mainly due to one-time pre-tax expenses related to a proposed settlement of a talcum powder lawsuit amounting to $5.519 billion.